I&I to Reorg in May for Summer Deployment

Total BS on any 2yr guarentee. I was a hiring manager with GI reps and we have never offered a 2yr guarentee.
False on that statement, go back to reading your "employment at will " contract

 

And heart attack and lung cancer

 

TOTAL BS!! I was hired as a GSR and there is no mention of 2 year guarantee. that's unheard of in pharma...

 

Everything is on pause awaiting FDA decision this Summer so likely Fall or Jan layoffs.
The rapid departure of the good tenure Pres Award winning reps , there will be no need of a 50% layoff as all the recent departures will take care of the right sizing.......
......oh wait, Lotz made decisions to backfill all positions not knowing if GI & AS will be canned.
Brilliant Einstein NOT decision
So YES now there will be massive layoffs when FDA is done w the CV 5yr coverup

 

Cover up by leaders— YES
For past 5 yrs— YES if not longer
FDA laying the hammer down with new label— YES
Pfizer needs 280 reps when first 2 yrs had 76– NO
Part Time 20 hr wk Flex rep w 1/2 pay coming— YES
Massive Layoffs coming Q4 -YES

 

The additional GI reps needed—NO

 

I’m not on the Xeljanz side so I don’t know about all the decisions. But I always wondered why the rheumatology force couldn’t call on G.I. It’s not like there are many in either specialty. It would be like adding a salesforce to Eliquis to call on pulmonologists and hematologists. It didn’t make sense. We just added them to the cardiologists we were already calling on and that was it. I think they’ll definitely be some reductions based on recent events and what the label will look like in the future.
As for Derm, it looks encouraging. Back to back products coming out in the next two years that are really promising treating debilitating diseases and are high dollar for the company. Calling on specialties that are influenced by face-to-face interactions definitely helps. I think if there’s any changes it’ll be to those territories with lower volume potential versus the territories that are pulling in the revenue.
But what confuses me is why they would change the structure of the entire organization in the middle of trying to successfully launch multiple products. If you’re going to do this, start with areas of the business that aren’t launching products. See what works and what doesn’t. Then apply those best practices to the launch divisions at a later time.

It’s like we are in this strange world of duality here at Pfizer.
We developed the 1st COVID vaccine, yet are the last company to return to normal.
We talk of being agile and diverse, yet we are going to this one size fits all model without looking at the facts on the ground.

Strange times...

 

What is going on in Derm? All we know if that all of Pfizer is going through a reorganization. How will this effect Derm? Yes know we have a direct partner...what will happen to that model?

 

I think it’s gonna depend on the area of the country and the volume. My territory was already a large volume one and literally doubled and some overnight. Realistically there is no way I would be able to cover what the company wants me to based on their own metrics. I think some territories in the “super states” with the volume and access are gonna need all hands on deck. Some of these territories with smaller volume and tough access may not need as many. The prob is gonna be all the little fiefdoms that want to protect their back yards.

 

Shouldn’t the product get approved first?

 

Ahh duh? Hope it didn’t take u too long to come up with that one.
But you need to be in the field I’d say a minimum of 4-6 weeks to get the pleasantries out of the way of explaining why we’ve been hiding in our houses for 14 months. This is a new product and a new class with competition out of the gate. We r gonna have field reimbursement people on the ground this time to assist. A lot of moving parts. And all of this has to be smooth and successful in the middle of reorganizing the entire company.

 

Well they are asking where we live. Assuming to see if it’s in your current territory. From experience rest is usually the beginning of the ball rolling.

 

who is asking where who lives?

 

LMAO I thought the same thing. First they know where we live, secondly nobody is asking. So many freaked out people. Just work....if we get laid off go find another job. We’ve had 14 months to invest in ourselves....hopefully many have and are prepared if we get laid off. We’ll never have that chance again to have months and months to invest in ourselves.

 

US Operations has froze everything for additional legal review of Reorg.
Timeline now moved to the Fall with Q4 target.

Divisions at highest risks with greatest % downsize are:
- IM Cluster (IM will go to 1 Cluster)
- Xeljanz (double reps 3yrs ago for GI that never became anything with CV label)
- Oncology RL

Covid Vaccine will continue selling itself without any reps.$$$$$$ pure profit

Oral Anti- Viral will go to Vaccine division for ER & Urgent Care. While the one remaining IM division will get it for FP & PC clinics.

 

Exactly. If anyone thinks that receiving full salary and benefits for over a year, while sitting home in your pjs, is an entitlement- then you totally missed the opportunity to update your resume and prepare for a new career.

 

Spot on Skippy!
Pfizer ONLY path to grow stock price (what CEO is only hired to do), is to increase NET PROFIT!
You do this with MORE Rev &/or LESS Expense.
Covid Vaccine will pull in 20 Billion next 12 months but Biden decision to eliminate vaccine patents yesterday will crash sales in 2022... so have 7m to bank 20 Billion.
Then Pfizer has to cut expenses to increase net profit as there are not any new blockbusters coming to mkt outside Oncology.
Many divisions like I&I Xeljanz & IM do not even have a pipeline of Phase 3 drugs for next 5yrs.

RESULTS will be a red Fall bloodbath in IM, Xeljanz, maybe the RLIO Oncology as they are just support overlap reps.